跳转至内容
Merck
CN
  • Orp8 deficiency in bone marrow-derived cells reduces atherosclerotic lesion progression in LDL receptor knockout mice.

Orp8 deficiency in bone marrow-derived cells reduces atherosclerotic lesion progression in LDL receptor knockout mice.

PloS one (2014-10-28)
Erik van Kampen, Olivier Beaslas, Reeni B Hildebrand, Bart Lammers, Theo J C Van Berkel, Vesa M Olkkonen, Miranda Van Eck
摘要

Oxysterol binding protein Related Proteins (ORPs) mediate intracellular lipid transport and homeostatic regulation. ORP8 downregulates ABCA1 expression in macrophages and cellular cholesterol efflux to apolipoprotein A-I. In line, ORP8 knockout mice display increased amounts of HDL cholesterol in blood. However, the role of macrophage ORP8 in atherosclerotic lesion development is unknown. LDL receptor knockout (KO) mice were transplanted with bone marrow (BM) from ORP8 KO mice and C57Bl/6 wild type mice. Subsequently, the animals were challenged with a high fat/high cholesterol Western-type diet to induce atherosclerosis. After 9 weeks of Western-Type diet feeding, serum levels of VLDL cholesterol were increased by 50% in ORP8 KO BM recipients compared to the wild-type recipients. However, no differences were observed in HDL cholesterol. Despite the increase in VLDL cholesterol, lesions in mice transplanted with ORP8 KO bone marrow were 20% smaller compared to WT transplanted controls. In addition, ORP8 KO transplanted mice displayed a modest increase in the percentage of macrophages in the lesion as compared to the wild-type transplanted group. ORP8 deficient macrophages displayed decreased production of pro-inflammatory factors IL-6 and TNFα, decreased expression of differentiation markers and showed a reduced capacity to form foam cells in the peritoneal cavity. Deletion of ORP8 in bone marrow-derived cells, including macrophages, reduces lesion progression after 9 weeks of WTD challenge, despite increased amounts of circulating pro-atherogenic VLDL. Reduced macrophage foam cell formation and lower macrophage inflammatory potential are plausible mechanisms contributing to the observed reduction in atherosclerosis.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
甲醇, suitable for HPLC, ≥99.9%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
甲醇, HPLC Plus, ≥99.9%
Sigma-Aldrich
胆固醇, Sigma Grade, ≥99%
Sigma-Aldrich
甲醇, anhydrous, 99.8%
Sigma-Aldrich
甲醇, Laboratory Reagent, ≥99.6%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Sigma-Aldrich
甲醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
苯酚 溶液, Equilibrated with 10 mM Tris HCl, pH 8.0, 1 mM EDTA, BioReagent, Molecular Biology
Sigma-Aldrich
甲醇, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
苯酚, puriss., ≥99.5% (GC), meets analytical specification of Ph. Eur., BP, USP, crystalline (detached)
Sigma-Aldrich
胆固醇, powder, BioReagent, suitable for cell culture, ≥99%
USP
木精, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
甲醇, BioReagent, ≥99.93%
Sigma-Aldrich
苯酚 溶液, Saturated with 0.01 M citrate buffer, pH 4.3 ± 0.2, BioReagent, Molecular Biology
Sigma-Aldrich
SyntheChol ® NS0 补充, 500 ×, synthetic cholesterol, animal component-free, sterile-filtered, aqueous solution, suitable for cell culture
Supelco
甲醇, analytical standard
Sigma-Aldrich
苯酚, ≥99%
Sigma-Aldrich
液状苯酚, ≥89.0%
Supelco
甲醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
苯酚, puriss. p.a., ACS reagent, reag. Ph. Eur., 99.0-100.5%
Supelco
苯酚, Pharmaceutical Secondary Standard; Certified Reference Material
USP
苯酚, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
胆固醇, from sheep wool, ≥92.5% (GC), powder
Sigma-Aldrich
苯酚, Molecular Biology
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Supelco
胆固醇, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
胆固醇 溶液, certified reference material, 10 mg/mL in chloroform